Dysplasia, Esophageal Cancer
Conditions
Keywords
EAC, HGD, Esophagus
Brief summary
To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization and the ability for targeted biopsies. Optical molecular imaging of neoplasia associated biomarkers could form a promising technique to accommodate this need. It is known that the biomarker Vascular Endothelial Growth Factor (VEGF) is overexpressed in dysplastic and neoplastic areas in BE segments versus normal tissue and has proven to be a valid target for molecular imaging. The University Medical Center Groningen (UMCG) developed a fluorescent tracer by labeling the VEGF-targeting humanized monoclonal antibody bevacizumab, currently used in anti-cancer therapy, with the fluorescent dye IRDye800CW. We hypothesize that when bevacizumab-IRDye800CW is administered, it accumulates in VEGF expressing high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), enabling early cancer visualization using a newly developed fluorescent NIR fiber-bundle. This hypothesis will be tested in this pilot intervention study.
Interventions
Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure. \* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)
A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
Sponsors
University Medical Center Groningen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Identified HGD or intramucosal EAC (T1) and therefore candidate for endoscopic mucosal resection therapy * Mentally competent person, 18 years or older. * Written informed consent. * Adequate potential for follow-up.
Exclusion criteria
* Medical or psychiatric conditions that compromise the patient's ability to give informed consent. * Submucosal and invasive EAC; EAC with tumor-classification other than T1. * Concurrent (uncontrolled) medical conditions which disqualify for an endoscopic mucosal resection procedure. * Previously performed therapeutic endoscopic procedures. * Pregnancy or breast feeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| NIR fluorescent signal in vivo (prior to EMR) | 1 day (endoscopy-day) | Evaluating presence of specific fluorescent signal in (pre)malignant esophageal lesion in vivo, with use of Near Infrared (NIR) fluorescence endoscopy platform. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events (AE), serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR). | Two days prior and up to 1 week after administration of tracer | Data collection as a measure of safety and tolerability regarding administration of Bevacizumab-IRDye800CW |
| VEGF expression ex vivo | up to 1 year | Correlation between specific fluorescent signal in vivo and ex vivo (observed with near-infrared fluorescence endoscopy) and VEGF expression ex vivo (immunohistochemistry). |
| NIR fluorescent signal in vivo (wound bed, post EMR) | 1 day (endoscopy-day) | Presence of specific fluorescence signal in correlation to histological evaluation of specimen (resection margins) |
| NIR fluorescent signal ex vivo (biopsy and EMR specimen) | up to 1 year | Evaluation of specific fluorescent signal ex vivo in correlation with observed fluorescence signal during endoscopy procedure. |
Countries
Netherlands
Outcome results
None listed